• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regenxbio Inc (NQ: RGNX )

    11.19 -0.51 (-4.36%)
    Streaming Delayed Price Updated: 12:33 PM EDT, Jul 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Regenxbio Inc

    < Previous 1 2 3 4 5 Next >
    Why Is Clearside Biomedical Stock Gaining Today?
    Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS... 
    Via Benzinga
    7 Biotech Stocks to Buy on the Dip: June 2024
    With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
    Via InvestorPlace
    FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
    The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations. 
    Via Benzinga
    Exposures Product Safety
    Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
    The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease. 
    Via Investor's Business Daily
    Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
    Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom. 
    Via Investor's Business Daily
    Exposures Product Safety
    Assessing Regenxbio: Insights From 4 Financial Analysts
    Via Benzinga
    Evaluating Regenxbio: Insights From 9 Financial Analysts
    Via Benzinga
    Where Regenxbio Stands With Analysts
    Via Benzinga
    Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
    Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
    Via Benzinga
    RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024
    RGNX stock results show that Regenxbio missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
    The threat is still emerging, but it could be significant. 
    Via The Motley Fool
    This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
    REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients. 
    Via Benzinga
    Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock
    Via Benzinga
    Regenxbio: Q4 Earnings Insights
    Via Benzinga
    Earnings Scheduled For February 27, 2024
    Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
    Via Benzinga
    A Preview Of Regenxbio's Earnings
    Via Benzinga
    REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars
    Latest updates on safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE trial for Duchenne muscular dystrophy. Positive results, no serious adverse events. Expect pivotal dose determination by... 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. 
    Via Benzinga
    Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
    U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
    Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer. 
    Via Benzinga
    The One-Minute Market Report - Sunday, Feb. 11
    In this brief market report, we will take a look at the various asset classes, sectors, equity categories, exchange-traded funds, and stocks that moved the market higher, as well as the market segments... 
    Via Talk Markets
    Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: 'You Might Be Missing Out On Some Huge Gains'
    Jim Cramer, the host of CNBC's "Mad Money," has suggested that investors should look beyond the Magnificent Seven tech stocks for potential high-yield investments. 
    Via Benzinga
    Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?
    Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction. 
    Via Benzinga
    Why Is Gene Therapy-Focused REGENXBIO Stock Trading Higher Today?
    REGENXBIO's progress in Duchenne muscular dystrophy and MPS II treatment trials. Interim results for RGX-202 in Phase 1/2 trial and significant milestones achieved in Phase 1/2/3 trial with RGX-121. 
    Via Benzinga
    Chipotle Posts Upbeat Earnings, Joins Cirrus Logic, Emerson Electric, Carlyle Group And Other Big Stocks Moving Higher On Wednesday
    U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Wednesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Container Store Group Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Shares of The Container Store Group, Inc. (NYSE: TCS) shares fell sharply during Wednesday’s session following weak quarterly results. 
    Via Benzinga
    Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness
    Regenxbio's latest trial data on ABBV-RGX-314 reveal 80% reduction in injection rate, 50% injection-free, and no intraocular inflammation. 
    Via Benzinga
    Progress Software Posts Strong Q4 Results, Joins Impinj, REGENXBIO And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
    U.S. stock futures were lower this morning, with the Dow Jones futures falling more than 100 points on Wednesday. Shares of Progress Software Corporation (NASDAQ: PRGS) rose in pre-market trading as... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.